Tyra Biosciences Inc

NASDAQ TYRA

Data sourced from

and

Download Data

Tyra Biosciences Inc Debt to Income Ratio 1 year YoY Change (%) for the Trailing 12 Months (TTM) ending September 20, 2024

Tyra Biosciences Inc Debt to Income Ratio 1 year YoY Change (%) is NA for the Trailing 12 Months (TTM) ending September 20, 2024. The debt to income ratio measures the level of debt relative to a company's net income. It is calculated by dividing total debt by net income. This ratio provides insights into the company's ability to generate sufficient income to cover its debt obligations. A higher ratio indicates a higher level of debt burden relative to the company's income. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.

NASDAQ: TYRA

Tyra Biosciences Inc

CEO	Dr. Todd Harris Ph.D.
IPO Date	Sept. 15, 2021
Location	United States
Headquarters	2656 State Street, Carlsbad, CA, United States, 92008
Employees	49
Sector	Healthcare
Industry	Biotechnology

Description

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

Key trends